Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

321.27 +5.49 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Insulet Corp (NASDAQ:PODD) Fits Minervini’s Trend Template with Strong Growth Momentum
Insulet Corp (PODD) aligns with Minervini's high-growth momentum strategy, showing strong technical uptrends, robust earnings growth, and solid revenue expansion. A top pick for investors seeking... 
Via Chartmill
Is the Market Bullish or Bearish on Insulet?
 
Via Benzinga
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 32.9% year on year to $649.1 million. On top of that,... 
Via StockStory
Topics World Trade
Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?
Boston Scientific stock rose to a record high in July and then consolidated. Prepping For a fresh run higher? 
Via Investor's Business Daily
Topics ETFs
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Looking Into Insulet's Recent Short Interest
 
Via Benzinga
Stay informed with the top movers within the S&P500 index on Thursday.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 32.9% year on year to $649.1 million. On top of that, next quarter’s... 
Via StockStory
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5
Insulet beats Q2 estimates with strong Omnipod growth and lifts 2025 revenue outlook on rising adoption and expanding global customer base. 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Applovin, Sunrun, Duolingo, Tutor Perini, Installed Building Products And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Thursday's session: gap up and gap down stock in the S&P500 index
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
Insulet (PODD) Q2 Revenue Jumps 33%
Via The Motley Fool
Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'
The company is still in the early stages of adding patients with type 2 diabetes to its client base. 
Via Investor's Business Daily
Insulet Corp. (NASDAQ:PODD) Delivers Strong Q2 2025 Earnings, Surpassing Revenue and EPS Forecasts
Insulet Corp. (PODD) reported strong Q2 2025 earnings, beating revenue and EPS estimates with $649.1M in sales and $1.17 adjusted EPS. Stock rose 4.58% pre-market. Raised full-year guidance signals... 
Via Chartmill
These S&P500 stocks are moving in today's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet (PODD) Q2 Earnings: What To Expect
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Thursday before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Years
 
Via Benzinga
Senator Mullin Discloses Stock Trades 2.5 Years After They Were Made, Including One Up 134.5%
 
Via Benzinga
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Healthcare Stock on Our Buy List and 2 to Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
An update on Sana Biotechnology. 
Via Benzinga
2 High-Flying Stocks to Target This Week and 1 to Avoid
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
From Insulet Corporation
Via Business Wire
2 Mid-Cap Stocks Worth Your Attention and 1 to Brush Off
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Supply Chain
3 Growth Stocks to Stash
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
Topics Artificial Intelligence
Stay informed with the top movers within the S&P500 index on Tuesday.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process. 
Via Investor's Business Daily
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.